in vitro News and Research

RSS

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that it has entered into a Cooperative Research and Development Agreement ("CRADA") with The Walter Reed Army Institute of Research.

2 Nov 2010

Inhibitex to present INX-189 data for HCV infections at AASLD Meeting

Inhibitex, Inc. announced today that three posters describing preclinical data on INX-189, the Company's nucleotide polymerase inhibitor in clinical development for the treatment of chronic hepatitis C (HCV) infections, will be presented by various scientists from the Company at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA.

2 Nov 2010

Isogenica enters collaborative agreement with University of Cambridge Professor

Isogenica Ltd today announced that it has entered into a collaborative agreement with Professor Sir Tom Blundell of the University of Cambridge.

2 Nov 2010

GSN closes $12M Series C financing

Gene Security Network, Inc. today announced the closing of its $12M Series C financing. The financing round was led by Sequoia Capital and included Claremont Creek Ventures, Founders Fund, and Lightspeed Venture Partners.

2 Nov 2010

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

Inappropriate growth and survival signaling, which leads to the aberrant growth of cancer cells, is a driving force behind tumors. Much of current cancer research focuses on the kinase enzymes whose mutations are responsible for such disregulated signaling, and many successful molecularly targeted anti-cancer therapeutics are directed at inhibiting kinase activity.

2 Nov 2010

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Rubicon Genomics today reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

2 Nov 2010

454 Life Sciences and DNA Electronics partner to develop high-throughput DNA sequencing system

454 Life Sciences, a Roche Company, announced today that it has entered an exclusive partnership with DNA Electronics for the development of a low-cost, high-throughput DNA sequencing system. As part of the agreement, Roche has signed a non-exclusive license for relevant IP from DNA Electronics' proprietary semiconductor technology portfolio, which enables sensitive detection of nucleotide incorporation during sequencing.

1 Nov 2010

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.

1 Nov 2010

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.

1 Nov 2010

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec Pharmaceuticals announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.

1 Nov 2010

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.

30 Oct 2010

Advaxis enters CRADA with NCI for development of live attenuated Listeria vaccines

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, is pleased to announce it has signed a formal research agreement with the National Cancer Institute at the National Institutes of Health.

30 Oct 2010

Study suggests curcumin may be an effective therapy for liver fibrosis

Curcumin, a chemical that gives curry its zing, holds promise in preventing or treating liver damage from an advanced form of a condition known as fatty liver disease, new Saint Louis University research suggests.

30 Oct 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron Corporation today reported financial results for the three and nine months ended September 30, 2010.

29 Oct 2010

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

Pharmasset, Inc. reported positive preliminary results today from its phase I monotherapy trial of PSI-352938 for the treatment of chronic hepatitis C (HCV). PSI-938 is a guanosine nucleotide analog polymerase inhibitor in development for the treatment of chronic HCV infection.

28 Oct 2010

Disinfection cap dispensing 70% isopropyl alcohol effectively disinfects IV needleless connectors

A study and review performed by clinicians of PICC Excellence, Inc. found a disinfection cap that dispenses 70% isopropyl alcohol is effective in disinfecting IV needleless connectors after five minutes. The study shows that if a needleless connector is covered and bathed in alcohol by the disinfection cap, no drying time is required to kill nearly all pathogens on the connector.

28 Oct 2010

AnaptysBio announces issuance of two new patents for SHM-XEL platform

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, announced the issuance of patents in the US and Europe that provide additional coverage for its SHM-XEL platform. These patents extend AnaptysBio's leadership in the use of somatic hypermutation (SHM) for the discovery and optimization of antibodies and other proteins.

28 Oct 2010

Epigenomics presents data on Septin9 biomarker clinical study for colorectal cancer at UEGW

Epigenomics AG, the cancer diagnostics company, announced that new data obtained in a clinical study with the Company's proprietary Septin9 biomarker for the blood-based detection of colorectal cancer, were presented yesterday at the 18th United European Gastroenterology Week (UEGW) in Barcelona, Spain.

28 Oct 2010

Study finds green tea does not protect breast cancer

Green tea does not protect against breast cancer. A study of data from approximately 54,000 women, published in BioMed Central's open access journal Breast Cancer Research, found no association between drinking green tea and breast cancer risk.

28 Oct 2010

in vitro News and Research

Advanced Life Sciences enters CRADA for Restanza with Walter Reed Army Institute of Research

Inhibitex to present INX-189 data for HCV infections at AASLD Meeting

Isogenica enters collaborative agreement with University of Cambridge Professor

GSN closes $12M Series C financing

New microfluidic in vitro kinase radioassay improves efficiency to detect cancer growth

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

454 Life Sciences and DNA Electronics partner to develop high-throughput DNA sequencing system

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Advaxis enters CRADA with NCI for development of live attenuated Listeria vaccines

Study suggests curcumin may be an effective therapy for liver fibrosis

Novel small molecule inhibitors may provide new therapy for colon cancer

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

Disinfection cap dispensing 70% isopropyl alcohol effectively disinfects IV needleless connectors

AnaptysBio announces issuance of two new patents for SHM-XEL platform

Epigenomics presents data on Septin9 biomarker clinical study for colorectal cancer at UEGW

Study finds green tea does not protect breast cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News